Member Info for Gheko

Re rate starting.

Micro cap at circa £7 million and only 95 million shares in issue.

Collaboration with US cancer institute will be reported on early this year is my prediction. Positive news there and name your price!

Nice link thank you gtc to FAb CSO rubbing shoulders with the whale companies in our sector plus the highly positive interview from our CEO.

Going to be a FAB 2025 and looks like other folk agree and we are off and running. Good luck all for 2025

Comparisons being made with the surge in ARB back in the day when they went from circa 4p in October to £2.50…yes £2.50!!

Not suggesting the same pattern but just a fraction of that excitement multibags here.

GTC. I think double that as a starter but with positive news from the US cancer institute then name your price for a take out. To a big pharma then 75 million plus is easily possible. A ten bagger from here.

Whatever the price it’s gojng multiples of where we are now me thinks.

Not surprised this is number two on the tip list from that site.

However the target of 15p is way too conservative in my analysis. Pivotal year of momentum for FAB in 2025.

News to come of the US National Cancer Institute assessment of our unique platform plus the other pillars of the companies strategy both human and mammalian.

Market cap a micro circa £6 million. So even at a conservative £30 million cap that is a share price of 28p.

Looking forward to the r3 rate in FAB coming soon in 2025. Good luck all.

Great run we are on and the re rate set to continue.

Chart showing upside to initial target of circa 2.9/3p which is about 30% upside from here.

Think the papers and financial journos may give us a mention in the new years tipster list which will attract more folk to the unfolding share of 2025 and beyond. Good luck all.

Momentum building fast here and with the work with the US National Cancer Institute plus the likely licence opportunities of the unique platforms then it is a real possibility in the short term that we will be taken out by a mid to major company.

That said the price is likely to be multiples of this share price. Great time to be invested here.

Great webinar presentation. A few takeaways for me.

1. The work around Optimal and Optiphage platforms. They could potentially be licensed to every biotech company in THE WORLD!! Hello, all aboard.

2.slip of the tongue when talking about the work with US National Cancer Institute. I got sense that they know it is a done deal. If that announcement comes then add then add an immediate 0 to the share price!

3. As a result of the grant funding where FAB are not paying for the equipment or upkeep they can look to grow margins.

4. When asked about potential news in next 3-6 months naturally very coy but I sensed he looking forward to lots of news.

5. Final comment was the grant gives FAB quote ‘a remarkable opportunity’.

Very happy with my investment and adding more tomorrow.

Yes thanks Lloyd for the link. Interesting when I clicked on the link to get the white paper it flashed across the screen Veeam Semnet!

Suspect they are working closely together so to be with a $15 billion dollar company is not bad company to keep ahead of flotation on Nasdaq.

Truly makes GST current valuation look like bargain of the century. Wakey wakey market et al.

Thanks Antha.

For me 10p doesn’t even begin to price in the announcement yesterday let alone the work with the US NCI. Folk taking their profits now are missing the huge upswing coming. Bought some more this morning. Bargain. Upside is huge

So just a summary of where we are after todays huge news:-

Only 95 million shares in issue

Market cap tiny at circa £5.6 million even after todays rise.

Already had cash runway into 25/26 with increasing deals

Evaluation of FAB tech with US National Cancer Institute still ongoing

NOW - todays RNS - turbo charge our technology in collaboration with top two universities in NI with big staff increase, £5 million of funding for equipment etc and £1 million upfront to the company in grant funding.

Easily a £50 million cap company already based on what we have. Imagine when the RNS lands with the National Cancer Institute of US joining up. Multiply that market cap by another 10.

Upside off the scale then. Happy to be holding and enjoying the re rate due.

Great find Board. £22 billion market. A slice of that please!

Check out in the presentation when the CEO talks about the valuation of antibodies. The smile is tangible and him referencing what he had put out in his LinkedIn about other companies value makes you wonder whether he knows that there is a very big chance of a big takeover offer out there. At circa £4 million cap the upside is mind blowing.

Sadly exactly as I posted recently. Begging bow l again and no vision as to when we monetise any of our holdings for the benefit of long suffering shareholders. Jam tomorrow company continues.

Sea - yes I get that about when Salt could be monetised but the others could have been and just seem to squander the money. Hope it comes good for you but seems an endless circle at moment.

A spike in price followed by drift back down again. Still no plan as to when TEK going to monetise some of its holdings in these companies for the benefit of long suffering shareholders.

Then the begging bowl comes round again. Rinse and repeat. So no matter how good the news from Salt, Lucyd etc without any direction on monetisation then price continues spike and fall.

Nice 1.7 million buy gone through. Read the last RNS and it’s obvious this is so so cheap.

Top of leader board but not showing on LSE yet. With that news today and a tiny market cap at this price of circa £17 million and now a spin off of semnet on Nasdaq I hear the hoofs of the herd rumbling our way.

Worth 3x this before even taking stock imho. Well done LTH s

Page 39 - “Belfast based FAB climbed 1/4p or 6.2 per cent to 4 1/4p as the company said it expected to report a rise in half year earnings. revenues at the provider of antibody development services are forecast to reach £1.2 million for the six months to September 30 up from £541,000 during the same period last year”.

Getting on the radar of a lot of investors.

Mentioned in the market report today in the Times. Mentions the big rise in revenue.

Looking very strong for a run here.

Half year revenues doubled. No plans for a raise and momentum building nicely.

Strong link with US National Cancer Institute. More news on that link and this 10 bags.